Timothy S. Pardee, MD, Assistant Professor, Hematology & Oncology, Wake Forest University Baptist Medical Center, describes initial results of the CALGB 10801 (Alliance) study, which added dasatinib to standard induction and consolidation therapy for newly diagnosed patients with core binding factor (CBF) acute myeloid leukemia (AML).
Timothy S. Pardee, MD, Assistant Professor, Hematology & Oncology, Wake Forest University Baptist Medical Center, describes initial results of the CALGB 10801 (Alliance) study, which added dasatinib to standard induction and consolidation therapy for newly diagnosed patients with core binding factor (CBF) acute myeloid leukemia (AML).
Clinical Pearls:
Cretostimogene Grenadenorepvec Shows High CR Rate in BCG-Unresponsive NMIBC
July 17th 2024Mark D. Tyson, II, MD, MPH, discussed treatment with cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ and data from the BOND-003 trial.
Read More